前列腺特异性膜抗原诊疗一体化在晚期前列腺癌中的应用:一种不断发展的选择
本文综述了前列腺特异性膜抗原(PSMA)放射配体治疗(RLT)在晚期前列腺癌患者中的数据。以PSMA为靶点的RLT是转移性去势抵抗性前列腺癌(mCRPC)现有治疗选项之外的一种有前景的治疗替代方案。前瞻性II期数据支持Lu-PSMA在经重度治疗进展的mCRPC男性中的安全性和有效性,多项后期随机试验正在进行中。
要点
- PSMA RLT是mCRPC患者有前景的新型治疗选择。
- 前瞻性II期数据支持Lu-PSMA在重度治疗mCRPC中的安全性和有效性。
- 多项Lu-PSMA后期随机试验正在进行,早期结果令人鼓舞。
核心结论
- PSMA RLT是mCRPC男性有前景的新型治疗选择,也可能在较轻阶段前列腺癌中有应用价值。
研究设计与样本
- 叙述性综述,聚焦PSMA作为RLT靶点及相关数据。
主要发现
- PSMA RLT是mCRPC现有管理选项之外令人兴奋的治疗替代方案。
- 大多数证据涉及小分子PSMA抑制剂与β发射放射性同位素如177Lu结合(Lu-PSMA)。
- 前瞻性II期数据支持Lu-PSMA在经重度治疗进展的mCRPC男性中的安全性和有效性。
- 多项Lu-PSMA后期随机试验正在进行中,更多试验在筹备中。
- 早期结果令人鼓舞,表明诊疗一体化方法可能在晚期前列腺癌管理中起重要作用,甚至可能在更早期疾病状态中。
临床怎么用
- 本综述为多学科团队提供前列腺癌诊疗一体化当前和潜在未来应用的更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. METHODS: Narrative review focussing on PSMA as a target for RLT, and data using RESULTS: RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate-resistant prostate cancer (mCRPC). To date, most evidence exists regarding small-molecule PSMA inhibitors bound to beta-emitting radioisotopes such as 177Lu (Lu-PSMA). Prospective phase II data supports the safety and efficacy of Lu-PSMA in men with heavily pre-treated progressive mCRPC, and several late-phase randomised trials of Lu-PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states. CONCLUSIONS: PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
引用
- Mayor N, Sathianathen NJ, Buteau J, et al. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020. PMID: 32559353. doi:10.1111/bju.15143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。